Multiple innovative pharmaceutical companies are approaching a profit turning point.

According to data from East Money Information, as of 4 pm on February 27th, a total of 24 innovative pharmaceutical companies have released their financial reports for the year 2025, with 19 of them reporting positive growth in net profit attributable to shareholders, accounting for 79.17%. Among them, BeiGene achieved its first annual profit in 2025 with a net profit attributable to shareholders of 1.422 billion yuan; MicroPort BioTech reported a net profit of 51.0757 million yuan in 2025, turning losses into profits. Yu Xiaoming, senior investment advisor at Jufeng Investment, stated that the turning point for profitability of domestic innovative pharmaceutical companies is beginning to show, with leading companies showing strong profitability certainty. However, there is noticeable differentiation within the industry, and the entire sector has not completely emerged from the loss cycle. Overall, the industry is in a phase of narrowing losses, breakthroughs by leading companies, and overall signs of recovery but with an unsteady foundation.